Skip to content

The influence of intraoperative intervention with subanesthetic dose of esketamine on postoperative pain and postpartum depression in women undergoing cesarean section

The influence of intraoperative intervention with subanesthetic dose of esketamine on postoperative pain and postpartum depression in women undergoing cesarean section

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500112236
Enrollment
Unknown
Registered
2025-11-11
Start date
2025-11-30
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Caesarean section

Interventions

Esketamine group:0.75% ropivacaine was given in the subarachnoid space and 0.3mg / kg esketamine 5min after fetal delivery
Saline group:Subarachnoid administration of 0.75% ropivacaine 2.3ml+0.15mg morphine mixture and 0.9% saline by intravenous infusion 5min after fetal delivery

Sponsors

Chinese People's Liberation Army Northern Theater Command General Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Age >=18 years old, pregnancy >=28 weeks; 2.ASA Class II; 3. The parturient can communicate well with the follow-up visitors. 4. Voluntarily participate in this study and sign the relevant informed consent.

Exclusion criteria

Exclusion criteria: 1. Those who cannot accurately understand VAS scores and EPDS scores; 2. There are mental disorders such as mental abnormalities; 3. Exclude parturients with an EPDS score greater than 9 and those with prenatal depression; 4. Possessing severe cardiovascular and cerebrovascular diseases as well as liver and kidney dysfunction; 5. Have a history of abuse of ketamine or other drugs; 6. Severe eclampsia; 7. Allergic to the drug in this trial

Design outcomes

Primary

MeasureTime frame
VAS score at 24 hours after surgery;

Secondary

MeasureTime frame
Vital sign;Adverse event;

Countries

China

Contacts

Public ContactLin Li

The General Hospital of the PLA Northern Theater Command

Lilin100@qq.com+86 159 0988 3195

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026